Market Risers: GlaxoSmithKline plc, Hardide Plc, Mediclinic International PLC, Mi-Pay Group PLC

Hardide Plc
[shareaholic app="share_buttons" id_name="post_below_content"]

Shares of GlaxoSmithKline plc with ticker code: LON:GSK has gained 1.1% or 16.2 points in today’s trading session so far. Investors seem confident during the session. The period high has peaked at 1486.6 while the low for the session was 1473.8. The total volume of shares traded by this point was 2,159,091 with the daily average at 9,600,207. A 52 week share price high is 1724.5 which comes in at 258.1 points different to the previous business close and a 52 week low sitting at 1179.39 which is a variance of 287.01 points. GlaxoSmithKline plc now has a 20 moving average of 1457.73 and a 50 day moving average of 1403.07. This puts the market cap at £74,058.11m at the time of this report. The currency for this stock is Great British pence.Market cap is measured in GBP. This article was written with the last trade for GlaxoSmithKline plc being recorded at Monday, May 14, 2018 at 1:12:24 PM GMT with the stock price trading at 1482.6 GBX.

 

 

Stock in Hardide Plc with ticker code: LON:HDD has moved up 7.95% or 0.14 points throughout today’s trading session so far. Market buyers have remained positive during the trading session. Range high for the period has seen 2.1 and a low of 1.9. The number of shares traded by this point in time totalled 1,808,119 whilst the daily average number of shares exchanged is just 351,943. The stock 52 week high is 2.27 some 0.44 points in difference to the previous days close of business and a 52 week low sitting at 1.45 which is a difference of 0.38 points. Market capitalisation is now £28.14m at the time of this report. The share price is in Great British pence. Mcap is measured in GBP. This article was written with the last trade for Hardide Plc being recorded at Monday, May 14, 2018 at 12:31:57 PM GMT with the stock price trading at 1.97 GBX.

 

 

The trading price for Mediclinic International PLC with ticker code: LON:MDC has gained 1.94% or 13.4 points throughout today’s trading session so far. Investors have stayed positive during the trading session. The period high was 708.4 dropping as low as 693.2. The number of shares traded by this point in time totalled 372,813 while the average shares exchanged is 1,766,287. The 52 week high for the shares is 890.18 which comes in at 198.98 points in difference on the previous days close and a 52 week low being 495.4 a difference of some 195.8 points. Mediclinic International PLC has a 20 day moving average of 682.39 and the 50 day moving average now of 626.67. The current market capitalisation is £5,215.66m at the time of this report. All share prices mentioned for this stock are traded in GBX. Mcap is measured in GBP. This article was written with the last trade for Mediclinic International PLC being recorded at Monday, May 14, 2018 at 1:09:03 PM GMT with the stock price trading at 704.6 GBX.

 

 

Shares of Mi-Pay Group PLC with ticker code: LON:MPAY has moved up 6.05% or 0.65 points throughout the session so far. Traders are a positive bunch throughout the trading session. The periods high has already touched 11.4 and hitting a low of 11.4. The total volume of shares exchanged so far has reached 10,000 with the daily average number around 20,801. The 52 week high for the shares is 20.5 about 9.75 points in difference to the previous days close of business and a 52 week low sitting at 8.3 is a variance of 2.45 points. Market capitalisation for the company is £3.71m at the time of this report. The currency for this stock is GBX. Market cap is measured in GBP. This article was written with the last trade for Mi-Pay Group PLC being recorded at Monday, May 14, 2018 at 9:59:40 AM GMT with the stock price trading at 11.4 GBX.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
    GSK's Arexvy vaccine receives approval in Japan to protect adults aged 50-59 at increased risk from severe RSV infection, expanding its coverage.
    GSK Plc reports Q3 2024 results with strong growth in Specialty Medicines offsetting lower Vaccine sales. Core earnings rose by 5%, despite Zantac charges.
    Hardide plc (LON: HDD) forecasts FY24 revenue at £4.7m, with improved H2 sales and a focus on driving growth through strategic business development.
    GSK's new antibiotic gepotidacin earns FDA's Priority Review, marking potential first new uUTI oral treatment in 20 years, with decision due March 2025.

      Search

      Search